<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29207632</article-id><article-id pub-id-type="pmc">5710912</article-id><article-id pub-id-type="publisher-id">20017</article-id><article-id pub-id-type="doi">10.18632/oncotarget.20017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fangzheng</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Chuner</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fengqin</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhimin</surname><given-names>Ye</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Quanquan</surname><given-names>Sun</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tongxin</surname><given-names>Liu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Min</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Wu</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bin</surname><given-names>Long</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aizawa</surname><given-names>Rihito</given-names></name><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sakamoto</surname><given-names>Masoto</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhenfu</surname><given-names>Fu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><aff id="A1"><sup>1</sup> Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Hangzhou, 310022, People&#x02019;s Republic of China</aff><aff id="A2"><sup>2</sup> Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Hangzhou, 310022, People&#x02019;s Republic of China</aff><aff id="A3"><sup>3</sup> Department of Radiology, Japanese Red Cross Fukui Hospital, Fukui, 918-8501 Japan</aff><aff id="A4"><sup>4</sup> Department of Breast Tumor Surgery, Zhejiang Cancer Hospital, Zhejiang Hangzhou, 310022, People&#x02019;s Republic of China</aff><aff id="A5"><sup>5</sup> Department of Physics, Zhejiang Cancer Hospital, Zhejiang Hangzhou, 310022, People&#x02019;s Republic of China</aff><aff id="A6"><sup>6</sup> Department of Pathology, Zhejiang Cancer Hospital, Zhejiang Hangzhou, 310022, People&#x02019;s Republic of China</aff><aff id="A7"><sup>7</sup> Department of Nuclear Medicine, Zhejiang Cancer Hospital, Zhejiang Hangzhou, 310022, People&#x02019;s Republic of China</aff><aff id="A8"><sup>8</sup> Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 606-8507, Kyoto, Japan</aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Fu Zhenfu, <email>fzf1000@163.com</email></corresp><fn id="FN1" fn-type="equal"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="collection"><day>31</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>7</day><month>8</month><year>2017</year></pub-date><volume>8</volume><issue>53</issue><fpage>91150</fpage><lpage>91161</lpage><history><date date-type="received"><day>5</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Fangzheng et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Although a multicenter, randomized study indicated that induction chemotherapy (IC) with docetaxel/cisplatin/fluorouracil (TPF) before concurrent chemoradiotherapy (CCRT) improves survival outcomes, it remains unclear whether TPF is the best IC regimen for treating locoregionally advanced nasopharyngeal carcinoma (NPC). Our aim was to compare the efficacy and toxicities of TPF vs. docetaxel/cisplatin (TP) IC followed by CCRT in patients with locoregionally advanced NPC. One hundred thirty-two patients with locoregionally advanced NPC received 21-day cycles of IC with either TPF or TP. Both were followed by intensity-modulated radiotherapy concurrent with the cisplatin treatment every 3 weeks. Three-year rates of locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were respectively 96.4%, 87.7%, 86.0%, and 94.7% for patients in the TPF arm patients and 90.3%, 91.9%, 85.2%, and 92.0% for patients in the TP arm. There were no differences in survival between the two arms. Multivariate analysis revealed the IC regimen was not an independent prognostic factor for any survival outcome. However, patients in the TP arm experienced fewer grade 3/4 toxicities. In sum, IC with docetaxel and cisplatin is associated with similar efficacy and less toxicity than the TPF regimen. Addition of fluorouracil to docetaxel plus cisplatin IC is therefore not recommended for patients with locoregionally advanced NPC.</p></abstract><kwd-group><kwd>nasopharyngeal carcinoma</kwd><kwd>induction chemotherapy</kwd><kwd>concurrent chemoradiotherapy</kwd><kwd>toxicity</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Nasopharyngeal carcinoma (NPC) is a common head and neck cancer in Southern China, Malaysia, and Singapore [<xref rid="R1" ref-type="bibr">1</xref>]. Radiotherapy (RT), the main treatment for non-disseminated NPC, results in 5-year overall survival (OS) rates of 90&#x02013;100% in stage I&#x02013;II and 60&#x02013;85% in stage III-IVB patients [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. However, over 70% of NPC patients are diagnosed with locoregionally advanced diseases, and survival outcomes are poor in these patients [<xref rid="R4" ref-type="bibr">4</xref>]. The advent of intensity-modulated radiotherapy (IMRT), improvements in radiological techniques, and the application of concurrent chemotherapy have improved locoregional control, and distant failure is now typically the main cause of mortality [<xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref>]. The efficacies of induction chemotherapy (IC), concurrent chemoradiotherapy (CCRT), and adjuvant chemotherapy (AC) have been compared. CCRT is a standard treatment for patients with locoregionally advanced NPC and results in better survival outcomes than RT alone [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>]. Because few patients completed all three treatment cycles, AC was not associated with therapeutic gain in these patients [<xref rid="R12" ref-type="bibr">12</xref>]. The combination of IC followed by CCRT has therefore been studied more extensively. Phase II studies revealed that IC together with CCRT increased locoregional control rates for locoregionally advanced NPC [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>]. OuYang <italic>et al.</italic> found that adding IC to CCRT treatment reduced distant metastasis and improved OS [<xref rid="R15" ref-type="bibr">15</xref>]. Additional research is needed to examine the efficacy of treatments that combine IC and CCRT.</p><p>It remains unclear which IC regimen is most effective in patients with locoregionally advanced NPC. IC with cisplatin and fluorouracil (PF) has been widely used as a first-line regimen in NPC patients for many years. However, PF did not improve survival compared to CCRT alone [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. Taxanes, which are microtubule inhibitors, inhibit cell division. Several randomized phase III trials reported that the addition of taxane to IC regimens with cisplatin alone (TP) or with cisplatin and 5-fluorouracil (TPF) improved treatment outcomes in patients with locoregionally advanced head and neck squamous cell cancer [<xref rid="R18" ref-type="bibr">18</xref>&#x02013;<xref rid="R20" ref-type="bibr">20</xref>]. A recent phase 3 multicenter, randomized trial published in Lancet Oncology indicated that the addition of docetaxel, cisplatin, and 5-flurouracil (TPF) to CCRT improved OS, failure-free survival, and distant metastases-free survival (DMFS) rates in patients with locoregionally advanced NPC compared to CCRT alone [<xref rid="R21" ref-type="bibr">21</xref>]. Kong <italic>et al.</italic> also recently demonstrated that the addition of TPF-based IC to CCRT improved survival outcomes in locoregionally advanced NPC patients in comparison with historical data [<xref rid="R22" ref-type="bibr">22</xref>].</p><p>Although TPF-based IC followed by CCRT results in better survival outcomes than CCRT alone, it remains unclear whether TPF is the best IC regimen for NPC patients. Here, we conducted a phase II study to compare the efficacy and tolerability of TPF vs. TP IC regimens followed by concurrent chemotherapy and IMRT for patients with locoregional advanced NPC.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Patient basic characteristics and therapy adherence</title><p>One hundred thirty-two eligible patients with locoregionally advanced NPC treated between January 2012 and January 2014 were randomly assigned to the TPF arm (<italic>n</italic> = 57) or the TP arm (<italic>n</italic> = 75). Basic patient demographic information and tumor characteristics are summarized in Table <xref ref-type="table" rid="T1">1</xref>. Patient and tumor characteristics were similar between the two treatment arms.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Basic patient demographic information and tumor characteristics</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Characteristic</th><th align="center" valign="middle" rowspan="1" colspan="1">TPF regimen</th><th align="center" valign="middle" rowspan="1" colspan="1">TP regimen</th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>X</italic><sup><italic>2</italic></sup></th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><italic>N</italic> = 57</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>N</italic> = 75</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.874</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.710</td><td align="center" valign="middle" rowspan="1" colspan="1">0.400</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Range</td><td align="center" valign="middle" rowspan="1" colspan="1">19&#x02013;63</td><td align="center" valign="middle" rowspan="1" colspan="1">22&#x02013;70</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Median</td><td align="center" valign="middle" rowspan="1" colspan="1">47</td><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c; 50</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265; 50</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WHO pathology</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.712</td><td align="center" valign="middle" rowspan="1" colspan="1">0.425</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Type I</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Type II</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Type III</td><td align="center" valign="middle" rowspan="1" colspan="1">52</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECOG performance status</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">0.882</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T stage*</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.560</td><td align="center" valign="middle" rowspan="1" colspan="1">0.465</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T3</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T4</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N stage*</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.980</td><td align="center" valign="middle" rowspan="1" colspan="1">0.372</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N1</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N2</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">57</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N3</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Clinical stage*</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.094</td><td align="center" valign="middle" rowspan="1" colspan="1">0.760</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Comorbidity</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.386</td><td align="center" valign="middle" rowspan="1" colspan="1">0.534</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group, *The 7th AJCC/UICC staging system.</p></table-wrap-foot></table-wrap></sec><sec id="s2_2"><title>Disease response</title><p>After IC, 18 patients (31.6%) displayed complete remission (CR), 37 (64.9%) displayed partial remission (PR), and 2 (3.5%) displayed stable disease (SD) for nasopharyngeal tumors in the TPF arm, while 23 (40.4%), 49 (65.3%), and 3 (4.0%) TP arm patients displayed CR, PR, and SD, respectively. For cervical metastatic lymph nodes, CR, PR, and SD rates were 36.8% (21/57), 61.4% (35/57), and 1.8% (1/57) in TPF arm patients and 38.7% (29/75), 58.7% (44/75), 2.6% (2/75) in TP arm patients, respectively. After the completion of IMRT, CR rates for nasopharyngeal tumors and neck metastatic lymph nodes were 91.2% and 94.7% in TPF arm patients and 92.0% and 93.3% in TP arm patients, respectively. No statistically significant differences in disease responses to treatment were found between two arms (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Therapy details for the two arms</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" rowspan="1" colspan="1">TPF regimen</th><th align="center" valign="middle" rowspan="1" colspan="1">TP regimen</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cycle of IC</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.928</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cycle of CC</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.659</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AC</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: IC, induction chemotherapy; CC, concurrent chemotherapy; AC, adjuvant chemotherapy; TP, docetaxel/cisplatin; TPF, docetaxel/cisplatin/fluorouracil.</p></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Tumor responses to treatment in the two arms</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Response</th><th colspan="2" align="center" valign="middle" rowspan="1">Nasopharyngeal tumor</th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th><th colspan="2" align="center" valign="middle" rowspan="1">Neck lymph node</th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">TPF (<italic>n</italic>, %)</th><th align="center" valign="middle" rowspan="1" colspan="1">TP (<italic>n</italic>, %)</th><th align="center" valign="middle" rowspan="1" colspan="1">TPF (<italic>n</italic>, %)</th><th align="center" valign="middle" rowspan="1" colspan="1">TP (<italic>n</italic>, %)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">IC</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CR</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (31.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (40.4)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.985</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (36.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (38.7)</td><td rowspan="3" align="center" valign="middle" colspan="1">0.910</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (64.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (65.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">35 (61.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (58.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SD</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (3.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (4.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CCRT</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CR</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (91.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (92.0)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.874</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (94.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (93.3)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.738</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (8.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (5.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (6.7)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; CR, complete remission; PR, partial remission; SD, stable disease; TP, docetaxel/cisplatin; TPF, docetaxel/cisplatin/fluorouracil.</p></table-wrap-foot></table-wrap></sec><sec id="s2_3"><title>Survival outcomes</title><p>Survival was assessed for all patients with locoregionally advanced NPC in follow-ups conducted after a median of 47 months (range, 13&#x02013;60 months). The estimated locoregional relapse-free survival (LR-RFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) rates were 93.0%, 90.1%, 85.5%, and 93.2%, respectively, after 3 years (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Kaplan-Meier estimates of survival in 132 NPC patients</title></caption><graphic xlink:href="oncotarget-08-91150-g001"/></fig><p>There were no statistically significant differences in LR-RFS, DMFS, PFS, or OS between the two arms (3-year LR-RFS: 96.4% vs. 90.3%, respectively, <italic>p</italic> = 0.199, Figure <xref ref-type="fig" rid="F2">2A</xref>; 3-year DMFS: 87.7% vs. 91.9%, respectively, <italic>p</italic> = 0.554, Figure <xref ref-type="fig" rid="F2">2B</xref>; 3-year PFS: 86.0% vs. 85.2%, respectively, <italic>p</italic>=0.835, Figure <xref ref-type="fig" rid="F2">2C</xref>; 3-year OS: 94.7% vs. 92%, respectively, Figure <xref ref-type="fig" rid="F2">2D</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Kaplan-Meier estimates of survival outcomes in TPF and TP arm NPC patients</title></caption><graphic xlink:href="oncotarget-08-91150-g002"/></fig><p>All patients finished a full course of radical IMRT and received 1-3 cycles of IC. One hundred nine (82.6%) patients received CC and 103 (78.0%) received AC. Differences in treatments between the two arms are listed in Table <xref ref-type="table" rid="T2">2</xref>.</p></sec><sec id="s2_4"><title>Analysis of treatment failure</title><p>Twenty-two patients experienced treatment failure. Among these patients, 6 (1 in the TPF arm and 5 in the TP arm) developed locoregional relapse, 6 (2 in the TPF arm and 4 in the TP arm) had locoregional relapse and distant metastases, and 10 (6 in the TPF arm and 4 in the TP arm) experienced distant relapse. Treatment failure modes in these patients are summarized in Table <xref ref-type="table" rid="T4">4</xref>. The median time to failure was 19 months (range, 8 to 39 months) for TPF arm patients versus 15 months (range, 6 to 55 months) for TP arm patients.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Treatment failure details</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Failure mode</th><th align="center" valign="middle" rowspan="1" colspan="1">TPF</th><th align="center" valign="middle" rowspan="1" colspan="1">TP</th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><italic>N</italic> = 57</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>N</italic> = 75</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Locoregional</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td rowspan="4" align="center" valign="middle" colspan="1">0.374</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Locoregional and distant</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Distant</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No failure</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">62</td></tr></tbody></table></table-wrap></sec><sec id="s2_5"><title>Prognostic factors</title><p>Patient age, patient gender, clinical stage, adjusted tumor (T) and lymph node (N) stage, comorbidities, and IC regimen were examined as potential prognostic factors. Factors that influenced survival outcomes were identified and their prognostic roles evaluated in univariate and multivariate analyses. Univariate analysis revealed that 3-year DMFS, PFS, and OS had higher predictive value in stage III NPC patients than in stage IVA-B patients (3-year DMFS: 95.2% vs. 81.3%, <italic>p</italic> = 0.005; PFS: 92.8% vs. 73.0%, <italic>p</italic> = 0.001; OS: 96.4% vs. 87.8%, <italic>p</italic> = 0.004), and age was associated with LR-RFS (Table <xref ref-type="table" rid="T5">5</xref>). Multivariate analysis indicated that age was an independent prognostic factor of LR-RFS (<italic>p</italic> = 0.035), and clinical stage was an independent predictor of DMFS (<italic>p</italic> = 0.010), PFS (<italic>p</italic> = 0.002), and OS (<italic>p</italic> = 0.011) (Table <xref ref-type="table" rid="T6">6</xref>).</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Factors predictive of survival outcomes in 132 NPC patients identified via univariate analysis</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">LRRFS (%)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">DMFS (%)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">PFS (%)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th><th align="center" valign="middle" rowspan="1" colspan="1">OS (%)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td colspan="2" align="left" valign="middle" rowspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.024</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.349</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.980</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.672</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c; 50</td><td align="center" valign="middle" rowspan="1" colspan="1">85</td><td align="center" valign="middle" rowspan="1" colspan="1">96.3</td><td align="center" valign="middle" rowspan="1" colspan="1">88.1</td><td align="center" valign="middle" rowspan="1" colspan="1">85.7</td><td align="center" valign="middle" rowspan="1" colspan="1">94.1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265; 50</td><td align="center" valign="middle" rowspan="1" colspan="1">47</td><td align="center" valign="middle" rowspan="1" colspan="1">87.0</td><td align="center" valign="middle" rowspan="1" colspan="1">93.6</td><td align="center" valign="middle" rowspan="1" colspan="1">85.1</td><td align="center" valign="middle" rowspan="1" colspan="1">91.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender</td><td colspan="2" align="left" valign="middle" rowspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.705</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.727</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.743</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.746</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">93.4</td><td align="center" valign="middle" rowspan="1" colspan="1">88.3</td><td align="center" valign="middle" rowspan="1" colspan="1">85.1</td><td align="center" valign="middle" rowspan="1" colspan="1">92.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">91.9</td><td align="center" valign="middle" rowspan="1" colspan="1">94.6</td><td align="center" valign="middle" rowspan="1" colspan="1">86.5</td><td align="center" valign="middle" rowspan="1" colspan="1">94.7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T stage</td><td colspan="2" align="left" valign="middle" rowspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.121</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.422</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.138</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.440</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T1&#x02013;2</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">97.0</td><td align="center" valign="middle" rowspan="1" colspan="1">91.2</td><td align="center" valign="middle" rowspan="1" colspan="1">91.2</td><td align="center" valign="middle" rowspan="1" colspan="1">94.1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T3&#x02013;4</td><td align="center" valign="middle" rowspan="1" colspan="1">98</td><td align="center" valign="middle" rowspan="1" colspan="1">91.6</td><td align="center" valign="middle" rowspan="1" colspan="1">89.7</td><td align="center" valign="middle" rowspan="1" colspan="1">83.5</td><td align="center" valign="middle" rowspan="1" colspan="1">92.9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N stage</td><td colspan="2" align="left" valign="middle" rowspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.256</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.356</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.939</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.560</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N0&#x02013;1</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">88.9</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">88.9</td><td align="center" valign="middle" rowspan="1" colspan="1">94.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N2&#x02013;3</td><td align="center" valign="middle" rowspan="1" colspan="1">114</td><td align="center" valign="middle" rowspan="1" colspan="1">93.6</td><td align="center" valign="middle" rowspan="1" colspan="1">88.5</td><td align="center" valign="middle" rowspan="1" colspan="1">83.5</td><td align="center" valign="middle" rowspan="1" colspan="1">93.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Clinical stage</td><td colspan="2" align="left" valign="middle" rowspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.082</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.005</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.001</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">83</td><td align="center" valign="middle" rowspan="1" colspan="1">96.4</td><td align="center" valign="middle" rowspan="1" colspan="1">95.2</td><td align="center" valign="middle" rowspan="1" colspan="1">92.8</td><td align="center" valign="middle" rowspan="1" colspan="1">96.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IVA/B</td><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="center" valign="middle" rowspan="1" colspan="1">86.8</td><td align="center" valign="middle" rowspan="1" colspan="1">81.3</td><td align="center" valign="middle" rowspan="1" colspan="1">73.0</td><td align="center" valign="middle" rowspan="1" colspan="1">87.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Comorbidity</td><td colspan="2" align="left" valign="middle" rowspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.503</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.219</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.267</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.898</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">108</td><td align="center" valign="middle" rowspan="1" colspan="1">93.3</td><td align="center" valign="middle" rowspan="1" colspan="1">88.9</td><td align="center" valign="middle" rowspan="1" colspan="1">84.2</td><td align="center" valign="middle" rowspan="1" colspan="1">93.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">91.3</td><td align="center" valign="middle" rowspan="1" colspan="1">95.8</td><td align="center" valign="middle" rowspan="1" colspan="1">91.5</td><td align="center" valign="middle" rowspan="1" colspan="1">91.7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IC regimen</td><td colspan="2" align="left" valign="middle" rowspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.199</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.554</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.835</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td rowspan="3" align="center" valign="middle" colspan="1">0.434</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TPF</td><td align="center" valign="middle" rowspan="1" colspan="1">57</td><td align="center" valign="middle" rowspan="1" colspan="1">96.4</td><td align="center" valign="middle" rowspan="1" colspan="1">87.7</td><td align="center" valign="middle" rowspan="1" colspan="1">86.0</td><td align="center" valign="middle" rowspan="1" colspan="1">94.7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TP</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">90.3</td><td align="center" valign="middle" rowspan="1" colspan="1">91.9</td><td align="center" valign="middle" rowspan="1" colspan="1">85.2</td><td align="center" valign="middle" rowspan="1" colspan="1">92.0</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: LRRFS, locoregional relapse-free survival; DMFS, distant metastases-free survival; PFS, progression-free survival; OS, overall survival; IC, induction chemotherapy; TP, docetaxel/cisplatin; TPF, docetaxel/cisplatin/fluorouracil.</p></table-wrap-foot></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><title>Effects of prognostic factors on survival outcomes in multivariate analysis</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Endpoint</th><th align="center" valign="middle" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">OS</td><td align="center" valign="middle" rowspan="1" colspan="1">III vs. IV</td><td align="center" valign="middle" rowspan="1" colspan="1">0.184</td><td align="center" valign="middle" rowspan="1" colspan="1">0.050&#x02013;0.679</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PFS</td><td align="center" valign="middle" rowspan="1" colspan="1">III vs. IV</td><td align="center" valign="middle" rowspan="1" colspan="1">0.242</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098&#x02013;0.594</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LRRFS</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 50 vs. &#x02265; 50 years</td><td align="center" valign="middle" rowspan="1" colspan="1">0.274</td><td align="center" valign="middle" rowspan="1" colspan="1">0.083&#x02013;0.911</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMFS</td><td align="center" valign="middle" rowspan="1" colspan="1">III vs. IV</td><td align="center" valign="middle" rowspan="1" colspan="1">0.247</td><td align="center" valign="middle" rowspan="1" colspan="1">0.086&#x02013;0.711</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: OS, overall survival; PFS, progression-free survival; LRRFS, locoregional recurrence-free survival; DMFS, distant metastasis-free survival.</p></table-wrap-foot></table-wrap></sec><sec id="s2_6"><title>Safety and toxicity</title><p>The most commonly observed complications included hematologic and non-hematologic side effects. During IC treatment (Table <xref ref-type="table" rid="T7">7</xref>), grade 3 or higher leukocytopenia and neutropenia were reported in 33 (57.9%) and 44 (77.2%) of TPF arm patients, respectively, and in 14 (24.6%) and 17 (22.7%) of TP arm patients, respectively; these complications were more common in TPF arm patients (<italic>p</italic> &#x0003c; 0.001). Additionally, more TPF arm patients suffered mucositis and diarrhea than did TP arm patients (17 vs. 7, <italic>p</italic> = 0.002; 19 vs. 5, <italic>p</italic> &#x0003c; 0.001). The frequency of other toxicities did not differ between patients in the two arms.</p><table-wrap id="T7" orientation="portrait" position="float"><label>Table 7</label><caption><title>Adverse events during IC in the two arms</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Adverse events</th><th colspan="5" align="center" valign="middle" rowspan="1">TPF arm</th><th colspan="5" align="center" valign="middle" rowspan="1">TP arm</th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>Z</italic></th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">0</th><th align="center" valign="middle" rowspan="1" colspan="1">1</th><th align="center" valign="middle" rowspan="1" colspan="1">2</th><th align="center" valign="middle" rowspan="1" colspan="1">3</th><th align="center" valign="middle" rowspan="1" colspan="1">4</th><th align="center" valign="middle" rowspan="1" colspan="1">0</th><th align="center" valign="middle" rowspan="1" colspan="1">1</th><th align="center" valign="middle" rowspan="1" colspan="1">2</th><th align="center" valign="middle" rowspan="1" colspan="1">3</th><th align="center" valign="middle" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hematologic</td><td colspan="10" align="left" valign="middle" rowspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Leukocytopenia</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;4.874</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Neutropenia</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;5.758</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Anemia</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">51</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.233</td><td align="center" valign="middle" rowspan="1" colspan="1">0.816</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Thrombocytopenia</td><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.278</td><td align="center" valign="middle" rowspan="1" colspan="1">0.781</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Liver function</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;1.066</td><td align="center" valign="middle" rowspan="1" colspan="1">0.286</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Renal function</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;1,147</td><td align="center" valign="middle" rowspan="1" colspan="1">0.251</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-hematologic</td><td colspan="10" align="left" valign="middle" rowspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mucositis</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;3.062</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dermatitis</td><td align="center" valign="middle" rowspan="1" colspan="1">52</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">69</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.158</td><td align="center" valign="middle" rowspan="1" colspan="1">0.874</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;3.850</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nausea/vomiting</td><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">67</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;1.644</td><td align="center" valign="middle" rowspan="1" colspan="1">0.100</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: IC, induction chemotherapy.</p></table-wrap-foot></table-wrap><p>Incidences of acute adverse events by type and grade after CCRT are shown in Table <xref ref-type="table" rid="T8">8</xref>. Frequencies of hematologic events, RT-related mucositis, and dermatitis did not differ between the two arms.</p><table-wrap id="T8" orientation="portrait" position="float"><label>Table 8</label><caption><title>Adverse events after CCRT in the two arms</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Adverse events</th><th colspan="5" align="center" valign="middle" rowspan="1">TPF arm</th><th colspan="5" align="center" valign="middle" rowspan="1">TP arm</th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>Z</italic></th><th rowspan="2" align="center" valign="middle" colspan="1"><italic>p</italic></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">0</th><th align="center" valign="middle" rowspan="1" colspan="1">1</th><th align="center" valign="middle" rowspan="1" colspan="1">2</th><th align="center" valign="middle" rowspan="1" colspan="1">3</th><th align="center" valign="middle" rowspan="1" colspan="1">4</th><th align="center" valign="middle" rowspan="1" colspan="1">0</th><th align="center" valign="middle" rowspan="1" colspan="1">1</th><th align="center" valign="middle" rowspan="1" colspan="1">2</th><th align="center" valign="middle" rowspan="1" colspan="1">3</th><th align="center" valign="middle" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hematologic</td><td colspan="10" align="left" valign="middle" rowspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Leukocytopenia</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.676</td><td align="center" valign="middle" rowspan="1" colspan="1">0.499</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Neutropenia</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;1.839</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Anemia</td><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">51</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.886</td><td align="center" valign="middle" rowspan="1" colspan="1">0.375</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Thrombocytopenia</td><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;1.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.371</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Liver function</td><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">69</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;1.935</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Renal function</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;1.147</td><td align="center" valign="middle" rowspan="1" colspan="1">0.251</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-hematologic</td><td colspan="10" align="left" valign="middle" rowspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mucositis</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.106</td><td align="center" valign="middle" rowspan="1" colspan="1">0.915</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dermatitis</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">53</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.105</td><td align="center" valign="middle" rowspan="1" colspan="1">0.916</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="middle" rowspan="1" colspan="1">51</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.815</td><td align="center" valign="middle" rowspan="1" colspan="1">0.415</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nausea/vomiting</td><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">64</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;0.215</td><td align="center" valign="middle" rowspan="1" colspan="1">0.830</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: CCRT, concurrent chemoradiotherapy.</p></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>DISCUSSION</title><p>In the present study, we found that both docetaxel/cisplatin IC before IMRT with concurrent cisplatin-based chemotherapy (TP arm) and docetaxel/cisplatin/fluorouracil IC before CCRT (TPF arm) result in similar survival outcomes. Additionally, incidences of leucocypenia, neutropenia, mucositis, and diarrhea (hematologic toxicities) were lower in TP arm patients than in TPF arm patients. Thus, the addition of fluorouracil to treatments with docetaxel plus cisplatin may not improve survival in patients with locoregionally advanced NPC.</p><p>Three-year LR-RFS, DMFS, PFS, and OS rates did not differ between the two treatment arms. Among the potential prognostic factors examined, we found that age was an independent prognostic factor of LR-RFS and clinical stage was an independent predictor of DMFS, PFS, and OS.</p><p>Since the TAX 323 and 324 studies established TPF as the most effective IC treatment for improving survival outcomes in head and neck cancer [<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>], a growing number of studies have examined IC regimens that include taxanes. Recently, Ma <italic>et al.</italic> reported that three cycles of TPF IC before CCRT significantly improved survival outcomes, with 3-year OS, failure-free survival, and DMFS rates of 92%, 80%, and 90%, respectively [<xref rid="R21" ref-type="bibr">21</xref>]. Kong <italic>et al.</italic> reported 3-year OS, PFS, DMFS, and LRFS rates of 94.8%, 78.2%, 90.5%, and 93.9%, respectively, for a TPF-based IC regimen in the treatment of locoregionally advanced NPC [<xref rid="R22" ref-type="bibr">22</xref>]. Hassan <italic>et al.</italic> found that the addition of TP-based IC to CCRT resulted in good local control of locoregionally advanced NPC with a manageable toxicity profile [<xref rid="R23" ref-type="bibr">23</xref>]. In a randomized phase II trial, Hui <italic>et al.</italic> demonstrated that 2 cycles of TP IC before CRT improved 3-year OS compared to CRT alone (94.1% vs. 67.7%) [<xref rid="R24" ref-type="bibr">24</xref>]. In another phase II trial of TP together with CCRT, Zhong <italic>et al.</italic> observed 3-year OS and PFS rates of 94.1% and 72.7%, respectively [<xref rid="R25" ref-type="bibr">25</xref>]. While treatment with docetaxel and cisplatin with or without fluorouracil has resulted in excellent survival outcomes as a first-line IC for locoregionally advanced NPC, few studies have compared the efficacy and safety of TP versus TPF followed by CCRT in these patients. We therefore conducted the present phase II study to compare the efficacy and tolerability of TPF versus TP with concurrent chemotherapy and IMRT in these patients. Our results demonstrated that either TPF or TP in combination with CCRT yielded similar survival outcomes.</p><p>Hematologic and non-hematologic toxicities were the most commonly observed complications during the treatment period. Incidences of grade 3 or higher leukocytopenia and neutropenia were lower in patients who received TP treatment than in those who received TPF (24.6% vs. 57.9% and 22.7% vs. 77.2%, respectively). The incidences of hematologic toxicities observed here in TPF-treated patients are similar to those observed in previous studies (ranging from 55&#x02013;83%) [<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R26" ref-type="bibr">26</xref>]. All patients in this study received prophylaxis leukocyte therapy using recombinant granulocyte colony-stimulating factor (GCFS), and patients who experienced grade 3/4 leukocytopenia and neutropenia during IC and could therefore continue with chemotherapy without delay. Non-hematological side effects, such as mucositis, dermatitis, diarrhea, and nausea/vomiting, were mild to moderate. Incidences of mucositis and diarrhea were lower in TP arm patients than in TPF arm patients (9.3% and 22.7% and 6.7% vs. 33.3%, respectively). Similar percentages of patients in the two treatment arms completed more than 2 cycles of IC.</p><p>In conclusion, our results suggest that TPF and TP IC regimens before IMRT plus concurrent chemotherapy yield similar disease responses and LR-RFS, DMFS, PFS, and OS rates in locoregionally advanced NPC, while TP results in a better toxicity profile. However, further randomized, controlled, multicenter phase III clinical trials are needed to assess the efficacy and toxicity of TP IC regimens.</p></sec><sec id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Patients and pretreatment</title><p>The patients enrolled in this study were hospitalized between January 2012 and January 2014 in the Department of Radiation Oncology, Zhejiang Cancer Hospital. Eligible patients met the following criteria: (i) histologically confirmed NPC; (ii) aged 18 to 70 years; (iii) stage III/IVA-B at diagnosis (American Joint Committee on Cancer staging system, 7th edition); (v) adequate bone marrow, liver and renal function; (vi) no previous anti-cancer treatment.</p><p>The exclusion criteria were as follows: aged 70 years or older; previously received RT, chemotherapy, or surgery for tumors; had distant metastases before treatment; were pregnant; history of other malignancy; severe comorbidities. This prospective randomized study was approved by the medical ethics committee of Zhejiang Cancer Hospital. All patients signed written informed consent before participating in this research.</p><p>Patients underwent a pretreatment evaluation that included collection of complete medical history, physical examination, hematology and biochemistry profiles, chest radiographs, sonography of the abdomen, bone scan, magnetic response imaging of the nasopharynx, and nosopharyngoscope. All patients were staged according to 2010 AJCC staging system. Tumor histology was classified according to the World Health Organization classifications.</p><p>Treatment details are shown in Figure <xref ref-type="fig" rid="F3">3</xref>. A total of 158 newly diagnosed locoregionally advanced NPC patients were randomly assigned to receive either the TPF or TP IC regimen before CCRT. The efficacy and toxicity of the two IC regimens in combination with CCRT were evaluated in 132 of these patients.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Trial profile</title></caption><graphic xlink:href="oncotarget-08-91150-g003"/></fig></sec><sec id="s4_2"><title>Treatment schemes</title><sec id="s4_2_1"><title>Radiation therapy</title><p>All patients were immobilized in a supine position with thermoplastic masks. Computed tomography scans with intravenous contrast (2.5 mm slices from the head to 2 cm below the sternoclavicular joints) were performed for planning purposes. Target volumes were delineated according to the recommendations of the International Commission on Radiation Units and Measurements CTV delineation protocol for head and neck malignancies [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>]. The delineation of NPC target volumes during the IMRT treatment was performed as described previously [<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>]. Gross tumor volume (GTV) referred to the extent of the tumor in clinical and imaging examinations. The extent of the primary tumor, including metastatic retropharyngeal lymph nodes, was defined as GTVnx, and the metastatic lymph nodes of the neck as GTVnd.</p><p>CTV was defined individually according to GTV and potential regions at risk surrounding the nasopharyngeal cavity. CTV for GTVnx included CTVnx for the high-risk CTV and CTV1 when invasion was present. CTVnx was defined as GTVnx plus a 7-mm margin that encompassed the nasopharyngeal mucosa plus 5 mm submucosal volume. For CTV1, the potentially involved anatomic regions were the entire nasopharyngeal cavity, the anterior one- to two-thirds of the clivus (when invasion was present, the whole clivus was covered), the skull base, the pterygoid plates, the parapharyngeal space, the inferior sphenoid sinus (the entire sphenoid sinus was be covered for stage T3 and T4 NPC), the posterior one-quarter to one-third of the nasal cavity, and the maxillary sinus. High-risk nodes included level Ib nodes in patients with metastatic lymph nodes in level IIa, and any lymph nodes in drainage pathways containing metastatic lymph nodes. Low-risk areas for prophylactic neck irradiation areas were referred as CTV2. These low-risk areas included levels IV and Vb without metastatic cervical lymph nodes.</p><p>PTV was constructed automatically based on each volume with an additional 3-mm margin in three dimensions to account for set-up variability. All PTVs, including PGTVnx, PTVnx, PTV1, and PTV2, were not delineated outside of the skin surface. Critical normal structures, including the brainstem, spinal cord, parotid glands, optic nerves, chiasm, lens, eyeballs, temporal lobes, temporomandibular joints, mandible, and hypophysis, were contoured and set as OARs during optimization.</p><p>All patients underwent radical IMRT with simultaneous integrated boost technique using 6 MV photons. The prescribed radiation dose was 70 or 72 Gy to PGTVnx, 66&#x02013;70 Gy to PGTVnd, 62&#x02013;66 Gy to PTVnx, 60&#x02013;63 Gy to PTV1, and 51&#x02013;54 Gy to PTV2, delivered in 30 or 33 fractions. Radiation was delivered once daily, five fractions per week, over 6&#x02013;6.5 weeks for IMRT planning. The dose to OAR was limited based on the RTOG 0225 protocol.</p></sec></sec><sec id="s4_3"><title>Chemotherapy regimens</title><p>All eligible patients were given one to three cycles of platinum-based induction chemotherapy at 3-week intervals. The TPF IC regimen consisted of docetaxel 60 mg/m<sup>2</sup>/day on day 1, cisplatin 25 mg/m<sup>2</sup>/day on days 1&#x02013;3, and 5-fluorouracil 500 mg/m<sup>2</sup>/day on days 1&#x02013;3; the TP IC regiment consisted of docetaxel 60 mg/m<sup>2</sup>/day on day 1 and cisplatin 25 mg/m<sup>2</sup>/day on days 1&#x02013;3.</p><p>NPC patients in this study also underwent &#x02265; 1 cycle of concurrent chemotherapy with cisplatin (80 mg/m<sup>2</sup>) divided over 3 days. One hundred three patients received 2&#x02013;3 courses of adjuvant chemotherapy with an FP (cisplatin 25 mg/m<sup>2</sup>/day on days 1&#x02013;3 and 5-fluorouracil 500 mg/m<sup>2</sup>/day on days 1&#x02013;3) regimen 3 weeks after RT.</p></sec><sec id="s4_4"><title>Patient evaluation and follow-up</title><p>Tumor responses were assessed three times: after the completion of induction chemotherapy, at the end of IMRT, and 3 months after radiation, which was based on MRI and nasopharynx fiberscope according to Response Evaluation Criteria for Solid Tumors criteria. Systemic chemotherapy adverse effects were graded using the National Cancer Institute Common Toxicity Criteria (NCI CTCAE, version 3.0), whereas RT-induced toxicities were scored according to the Acute and Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group (RTOG).</p><p>All the subjects underwent weekly examinations for treatment response and toxicities during radiation therapy. Patient followed-ups occurred every 3 months for the first 2 years, every 6 months from the third to the fifth year, and annually thereafter. Each follow-up included careful examination of the nasopharynx and neck nodes by an experienced doctor, MRI scan of the nasopharynx, nasopharynx fiberscope, chest computed tomography radiograph, and ultrasound of abdomen performed 3 months after the completion of RT and every 6&#x02013;12 months thereafter. Additional examinations were performed as needed to evaluate local relapse or distant metastasis.</p></sec><sec id="s4_5"><title>Statistical analysis</title><p>The end points of this study included LRRFS, DMFS, PFS, OS, and acute toxicities from IC and CCRT. OS was calculated from the date of enrollment to the date of death or the last follow-up. LRRFS, DMFS, and PFS were calculated from the date of enrollment to the date of locoregional relapse, distant metastasis occurrence, diagnosed evidence of disease progression, or the last follow-up. After recurrence or metastasis, patients were given salvage therapy as determined by their physicians.</p><p>Descriptive statistics were used to compare the patients&#x02019; characteristics, treatment adherence, tumor response, and patterns of failure between the two arms. Two independent sample non-parametric tests were used to compared acute toxicity between the two arms. Survival curves were generated using the Kaplan-Meier method. The curves were compared using log-rank tests. Multivariate analysis was performed using Cox regression models to identify significant prognostic factors. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for each prognostic factor. IBM SPSS Statistics version 19.0 was used for all data analysis. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS AND FUNDING</title><p>This study was supported by grants from the Medical Science Foundation of the Zhejiang Health Bureau (No.2013KYB033, No. 2009B026, No.2006A016, No.2005B012, No. 2004B014) and the National Natural Science Foundation of China (No. 81502646, No. 81502647).</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>The authors declare that there are no conflicts of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Xue</surname><given-names>WQ</given-names></name><name name-style="western"><surname>He</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>RS</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>YX</given-names></name><name name-style="western"><surname>Jia</surname><given-names>WH</given-names></name></person-group><article-title>Global trends in incidence and mortality of nasopharyngeal carcinoma</article-title><source>Cancer Letters</source><year>2016</year><volume>374</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">26828135</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>AW</given-names></name><name name-style="western"><surname>Ng</surname><given-names>WT</given-names></name><name name-style="western"><surname>Chan</surname><given-names>LK</given-names></name><name name-style="western"><surname>Chan</surname><given-names>OS</given-names></name><name name-style="western"><surname>Hung</surname><given-names>WM</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>PT</given-names></name><name name-style="western"><surname>Sze</surname><given-names>H</given-names></name><name name-style="western"><surname>Lam</surname><given-names>TS</given-names></name><name name-style="western"><surname>Yau</surname><given-names>TK</given-names></name></person-group><article-title>The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal carcinoma and suggestions for future improvement</article-title><source>Oral Oncol</source><year>2012</year><volume>48</volume><fpage>1007</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">22525607</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Mao</surname><given-names>YP</given-names></name><name name-style="western"><surname>Xie</surname><given-names>FY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>LL</given-names></name><name name-style="western"><surname>Lin</surname><given-names>AH</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China</article-title><source>Radiother Oncol</source><year>2012</year><volume>104</volume><fpage>331</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22103978</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>YP</given-names></name><name name-style="western"><surname>Xie</surname><given-names>FY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>LL</given-names></name><name name-style="western"><surname>Liao</surname><given-names>XB</given-names></name><name name-style="western"><surname>Xu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Lai</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>AH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2009</year><volume>73</volume><fpage>1326</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">19153016</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Du</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name></person-group><article-title>Intensity-modulated radiation therapy versus 2D-RT or 3D-RT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis</article-title><source>Oral Oncol</source><year>2015</year><volume>51</volume><fpage>1041</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">26296274</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J</given-names></name><name name-style="western"><surname>Garden</surname><given-names>AS</given-names></name><name name-style="western"><surname>Straube</surname><given-names>W</given-names></name><name name-style="western"><surname>Glisson</surname><given-names>B</given-names></name><name name-style="western"><surname>Xia</surname><given-names>P</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>W</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>WH</given-names></name><name name-style="western"><surname>Quivey</surname><given-names>J</given-names></name><name name-style="western"><surname>Thorstad</surname><given-names>W</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C</given-names></name><name name-style="western"><surname>Ang</surname><given-names>KK</given-names></name></person-group><article-title>Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trail 0225</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>3684</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">19564532</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wei</surname><given-names>B</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K</given-names></name></person-group><article-title>Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Treatment outcomes of a prospective, multicentric clinical study</article-title><source>Radiother Oncol</source><year>2014</year><volume>112</volume><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">24933452</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>AW</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JC</given-names></name><name name-style="western"><surname>Ng</surname><given-names>WT</given-names></name></person-group><article-title>Current management of nasopharyngeal carcinoma</article-title><source>Semin Radiat Oncol</source><year>2012</year><volume>22</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">22687948</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Sarraf</surname><given-names>M</given-names></name><name name-style="western"><surname>LeBlanc</surname><given-names>M</given-names></name><name name-style="western"><surname>Giri</surname><given-names>PG</given-names></name><name name-style="western"><surname>Fu</surname><given-names>KK</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J</given-names></name><name name-style="western"><surname>Vuong</surname><given-names>T</given-names></name><name name-style="western"><surname>Forastiere</surname><given-names>AA</given-names></name><name name-style="western"><surname>Adams</surname><given-names>G</given-names></name><name name-style="western"><surname>Sakr</surname><given-names>WA</given-names></name><name name-style="western"><surname>Schuller</surname><given-names>DE</given-names></name><name name-style="western"><surname>Ensley</surname><given-names>JF</given-names></name></person-group><article-title>Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup 0099</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>1310</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">9552031</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>AW</given-names></name><name name-style="western"><surname>Lau</surname><given-names>WH</given-names></name><name name-style="western"><surname>Tung</surname><given-names>SY</given-names></name><name name-style="western"><surname>Chua</surname><given-names>DT</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Siu</surname><given-names>L</given-names></name><name name-style="western"><surname>Sze</surname><given-names>WM</given-names></name><name name-style="western"><surname>Leung</surname><given-names>TW</given-names></name><name name-style="western"><surname>Sham</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ngan</surname><given-names>RK</given-names></name><name name-style="western"><surname>Law</surname><given-names>SC</given-names></name><name name-style="western"><surname>Yau</surname><given-names>TK</given-names></name></person-group><article-title>Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group</article-title><source>J Clin Oncol</source><year>2005</year><volume>25</volume><fpage>6966</fpage><lpage>6975</lpage></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wee</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>EH</given-names></name><name name-style="western"><surname>Tai</surname><given-names>BC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>HB</given-names></name><name name-style="western"><surname>Leong</surname><given-names>SS</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T</given-names></name><name name-style="western"><surname>Chua</surname><given-names>ET</given-names></name><name name-style="western"><surname>Yang</surname><given-names>E</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KM</given-names></name><name name-style="western"><surname>Fong</surname><given-names>KW</given-names></name><name name-style="western"><surname>Tan</surname><given-names>HS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KS</given-names></name><name name-style="western"><surname>Loong</surname><given-names>S</given-names></name></person-group><article-title>Randomized trial of radiotherapy versus concurrent chemoradiotherapy followd by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>6730</fpage><lpage>6738</lpage><pub-id pub-id-type="pmid">16170180</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Hu</surname><given-names>GQ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>WX</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name><name name-style="western"><surname>Xie</surname><given-names>FY</given-names></name><name name-style="western"><surname>Liang</surname><given-names>SB</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>TT</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name></person-group><article-title>Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><fpage>163</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">22154591</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fountzilas</surname><given-names>G</given-names></name><name name-style="western"><surname>Cluleanun</surname><given-names>E</given-names></name><name name-style="western"><surname>Bobos</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalogera-Fountzila</surname><given-names>A</given-names></name><name name-style="western"><surname>Eleftheraki</surname><given-names>AG</given-names></name><name name-style="western"><surname>Karayannopoulou</surname><given-names>G</given-names></name><name name-style="western"><surname>Zaramboukas</surname><given-names>T</given-names></name><name name-style="western"><surname>Nikolaou</surname><given-names>A</given-names></name><name name-style="western"><surname>Markou</surname><given-names>K</given-names></name><name name-style="western"><surname>Resiga</surname><given-names>L</given-names></name><name name-style="western"><surname>Dionysopoulos</surname><given-names>D</given-names></name><name name-style="western"><surname>Samantas</surname><given-names>E</given-names></name><name name-style="western"><surname>Athanassiou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patents with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">21525406</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>PY</given-names></name><name name-style="western"><surname>Cao</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Mo</surname><given-names>HY</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Deng</surname><given-names>MQ</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>F</given-names></name><name name-style="western"><surname>Cao</surname><given-names>SM</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>NW</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R</given-names></name><etal/></person-group><article-title>A randomized trial of induction chemotherapy plus concurrent chemotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma</article-title><source>Oral Oncol</source><year>2012</year><volume>48</volume><fpage>1034</fpage><lpage>1044</lpage></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>OuYang</surname><given-names>PY</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>Mao</surname><given-names>YP</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>XX</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xie</surname><given-names>FY</given-names></name></person-group><article-title>Significant efficacies of neoadjuvant chemotherapy and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, control trials</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><fpage>2136</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">23613477</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baujat</surname><given-names>B</given-names></name><name name-style="western"><surname>Audry</surname><given-names>H</given-names></name><name name-style="western"><surname>Bourhis</surname><given-names>J</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name><name name-style="western"><surname>Onat</surname><given-names>H</given-names></name><name name-style="western"><surname>Chua</surname><given-names>DT</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>DL</given-names></name><name name-style="western"><surname>Al-Sarraf</surname><given-names>M</given-names></name><name name-style="western"><surname>Chi</surname><given-names>KH</given-names></name><name name-style="western"><surname>Hareyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Leung</surname><given-names>SF</given-names></name><name name-style="western"><surname>Thephamongkhol</surname><given-names>K</given-names></name><name name-style="western"><surname>Pignon</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>64</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">16377415</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanchard</surname><given-names>P</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name><name name-style="western"><surname>Marguet</surname><given-names>S</given-names></name><name name-style="western"><surname>Leclercq</surname><given-names>J</given-names></name><name name-style="western"><surname>Ng</surname><given-names>WT</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name><name name-style="western"><surname>Huang</surname><given-names>PY</given-names></name><name name-style="western"><surname>Benhamou</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name><name name-style="western"><surname>Chua</surname><given-names>DT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mai</surname><given-names>HQ</given-names></name><etal/></person-group><article-title>Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><fpage>645</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">25957714</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermorken</surname><given-names>JB</given-names></name><name name-style="western"><surname>Remenar</surname><given-names>E</given-names></name><name name-style="western"><surname>van Herpen</surname><given-names>C</given-names></name><name name-style="western"><surname>Gorlia</surname><given-names>T</given-names></name><name name-style="western"><surname>Mesia</surname><given-names>R</given-names></name><name name-style="western"><surname>Degardin</surname><given-names>M</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>JS</given-names></name><name name-style="western"><surname>Jelic</surname><given-names>S</given-names></name><name name-style="western"><surname>Betka</surname><given-names>J</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>JH</given-names></name><name name-style="western"><surname>van den Weyngaert</surname><given-names>D</given-names></name><name name-style="western"><surname>Awada</surname><given-names>A</given-names></name><name name-style="western"><surname>Cupissol</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>1695</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">17960012</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posner</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hershock</surname><given-names>DM</given-names></name><name name-style="western"><surname>Blajman</surname><given-names>CR</given-names></name><name name-style="western"><surname>Mickiewicz</surname><given-names>E</given-names></name><name name-style="western"><surname>Winquist</surname><given-names>E</given-names></name><name name-style="western"><surname>Gorbounova</surname><given-names>V</given-names></name><name name-style="western"><surname>Tjulandin</surname><given-names>S</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>K</given-names></name><name name-style="western"><surname>Ervin</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>BA</given-names></name><name name-style="western"><surname>Raez</surname><given-names>LE</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>1705</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17960013</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pointreau</surname><given-names>Y</given-names></name><name name-style="western"><surname>Garaud</surname><given-names>P</given-names></name><name name-style="western"><surname>Chapet</surname><given-names>S</given-names></name><name name-style="western"><surname>Sire</surname><given-names>C</given-names></name><name name-style="western"><surname>Tuchais</surname><given-names>C</given-names></name><name name-style="western"><surname>Tortochaux</surname><given-names>J</given-names></name><name name-style="western"><surname>Faivre</surname><given-names>S</given-names></name><name name-style="western"><surname>Guerrif</surname><given-names>S</given-names></name><name name-style="western"><surname>Alfonsi</surname><given-names>M</given-names></name><name name-style="western"><surname>Calais</surname><given-names>G</given-names></name></person-group><article-title>Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation</article-title><source>J Natl Cancer Inst</source><year>2009</year><volume>101</volume><fpage>498</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">19318632</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>WF</given-names></name><name name-style="western"><surname>Chen</surname><given-names>NY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Hu</surname><given-names>GQ</given-names></name><name name-style="western"><surname>Xie</surname><given-names>FY</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XY</given-names></name><name name-style="western"><surname>Li</surname><given-names>JG</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Hu</surname><given-names>CS</given-names></name><name name-style="western"><surname>Xu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Induction chemotherapy plus concurrent chemotherapy versus concurrent chemoradiotheray alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial</article-title><source>Lancet Oncol</source><year>2016</year><volume>12</volume><fpage>1509</fpage><lpage>1520</lpage></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YW</given-names></name><name name-style="western"><surname>Hu</surname><given-names>CS</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>JJ</given-names></name></person-group><article-title>Effects of induction doctetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: final results of 2 parallel phase clinical trial</article-title><source>Cancer</source><year>2017</year><comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cncr.30566">https://doi.org/10.1002/cncr.30566</ext-link></comment></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>E</given-names></name><name name-style="western"><surname>Galai</surname><given-names>K</given-names></name><name name-style="western"><surname>Esmat</surname><given-names>E</given-names></name></person-group><article-title>Neo-adjuvant docetaxel and cisplatin followed by concurrent cisplatin with radiation therapy in treatment of locally advanced nasopharyngeal carcinoma</article-title><source>Gulf J Oncolog</source><year>2008</year><volume>10</volume><fpage>46</fpage><lpage>53</lpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>EP</given-names></name><name name-style="western"><surname>Ma</surname><given-names>BB</given-names></name><name name-style="western"><surname>Leung</surname><given-names>SF</given-names></name><name name-style="western"><surname>King</surname><given-names>AD</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F</given-names></name><name name-style="western"><surname>Kam</surname><given-names>MK</given-names></name><name name-style="western"><surname>Yu</surname><given-names>BK</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>WH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>R</given-names></name><name name-style="western"><surname>Chan</surname><given-names>I</given-names></name><name name-style="western"><surname>Ahuja</surname><given-names>AT</given-names></name><name name-style="western"><surname>Zee</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>242</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19064973</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>YH</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XY</given-names></name><name name-style="western"><surname>Xie</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>YF</given-names></name></person-group><article-title>Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>71</volume><fpage>1577</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">23549883</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>WK</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>JE</given-names></name><name name-style="western"><surname>Shim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Cho</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lim</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WK</given-names></name><name name-style="western"><surname>Chung</surname><given-names>IJ</given-names></name></person-group><article-title>Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2010</year><volume>65</volume><fpage>589</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">19830427</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>International Commission on Radiation Units and Measurements</collab></person-group><source>Prescribing, recording, and reporting photon beam therapy</source><publisher-loc>Bethesda</publisher-loc><publisher-name>ICRU</publisher-name><year>1993</year></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>International Commission on Radiation Units and Measurements</collab></person-group><source>Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50)</source><publisher-loc>Bethesda</publisher-loc><publisher-name>ICRU</publisher-name><year>1999</year></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fangzheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Chuner</surname><given-names>J</given-names></name><name name-style="western"><surname>Lei</surname><given-names>W</given-names></name><name name-style="western"><surname>Weijun</surname><given-names>C</given-names></name><name name-style="western"><surname>Min</surname><given-names>X</given-names></name><name name-style="western"><surname>Quanquan</surname><given-names>S</given-names></name><name name-style="western"><surname>Tongxin</surname><given-names>L</given-names></name><name name-style="western"><surname>Aizawa</surname><given-names>R</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhenfu</surname><given-names>F</given-names></name></person-group><article-title>Outcome and long-term efficacy of four facio-cervical fields conformal radiotherapy for nasopharyngeal carcinoma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>39756</fpage><lpage>39765</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.14403">https://doi.org/10.18632/oncotarget.14403</ext-link></comment><pub-id pub-id-type="pmid">28055973</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>FZ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ye</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Sun</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>TX</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Shi</surname><given-names>KY</given-names></name><name name-style="western"><surname>Long</surname><given-names>B</given-names></name><name name-style="western"><surname>Rihito</surname><given-names>A</given-names></name><name name-style="western"><surname>Masoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name></person-group><article-title>Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>75544</fpage><lpage>75556</lpage><comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.17357">https://doi.org/10.18632/oncotarget.17357</ext-link></comment><pub-id pub-id-type="pmid">29088889</pub-id></element-citation></ref></ref-list></back></article>